Cited by 408Treatment of Major DepressionNeurogenesis and neuroplasticity mechanismsStress Responses and Cortisol

The DOI matches its Crossref record; 217 of the 227 references it cites were found in a registry or an index; 13 of the 220 sources its claims cite were checked for support.

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications

Open access

Abstract

Major depressive disorder (MDD) was previously hypothesized to be a disease of monoamine deficiency in which low levels of monoamines in the synaptic cleft were believed to underlie depressive symptoms. More recently, however, there has been a paradigm shift toward a neuroplasticity hypothesis of depression in which downstream effects of antidepressants, such as increased neurogenesis, contribute to improvements in cognition and mood. This review takes a top-down approach to assess how changes in behavior and hippocampal-dependent circuits may be attributed to abnormalities at the molecular, structural, and synaptic level. We conclude with a discussion of how antidepressant treatments share a common effect in modulating neuroplasticity and consider outstanding questions and future perspectives.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01520-y

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

104 Not checked yet · 26 Own interpretation · 6 Partly supported · 1 Supported · 1 No basis given · accuracy not yet measured

Verify all 207 references — free account

Show all 83 claims

  • It may state two separate claims as one. 50
  • Probably not a substantial claim. 10
55 of 55
  • The paper relies on this without support.

    Antidepressant medications are pharmacologically active within hours, but their antidepressant effects are not apparent for weeks after starting treatment.

    “First, although these medications are pharmacologically active within hours, their antidepressant effects are not apparent for weeks after starting treatment.”
  • The paper relies on this without support.

    Even when antidepressants have meaningful pharmacologic effects, many patients do not improve.

    “Second, even when the medications are having meaningful pharmacologic effects, many patients do not improve.”
  • The authors state this as an assumption.

    The effects of antidepressants depend on downstream processes, such as increased neurogenesis, that take time to appear and are robust only in medication responders.

    “The most widely accepted response to both questions is to assume that the effects of antidepressants are dependent on downstream processes, such as an increase in neurogenesis, that take time to appear and are only robust in medication responders.”
  • The paper relies on this without support.

    High concentrations of hippocampal glucocorticoid receptors make the hippocampus particularly vulnerable to allostatic load.

    “Third, given its role in HPA axis regulation, the high concentrations of hippocampal glucocorticoid receptors make it particularly vulnerable to allostatic load.”
  • The paper relies on this without support.

    Hippocampal volume loss is not pathognomonic for depression and can occur in the presence of environmental stressors, other psychiatric conditions, and neurodegenerative diseases.

    “Hippocampal volume loss is not pathognomonic for depression and can occur in the presence of environmental stressors, other psychiatric conditions, and neurodegenerative diseases.”
  • The paper relies on this without support.

    Traditional antidepressants act on the monoaminergic system to increase synaptic monoamine neurotransmitter levels.

    “As previously discussed, traditional antidepressants target the monoaminergic system to increase levels of monoaminergic neurotransmitters in the synapse.”
  • The paper relies on this without support.

    To increase LTP, some NMDA receptors must remain available.

    “The dosage and affinity are important because, to increase LTP, some NMDA receptors must be available.”
  • The paper relies on this without support.

    Neuroplasticity is integral to healthy cognitive and affective functioning.

    “Neuroplasticity is integral to healthy cognitive and affective functioning.”
  • The paper relies on this without support.

    Major depressive disorder clinical heterogeneity remains poorly understood, particularly how it relates to pathogenesis and treatment choices.

    “MDD clinical heterogeneity remains poorly understood, particularly in terms of how it relates to pathogenesis and implications for treatment choices.”
  • The paper relies on this without support.

    The duration or presence of major depression correlates with declines in neuroplasticity.

    “While duration or presence of major depression correlates with declines in neuroplasticity, administration of antidepressants may reverse some of the neurobiological changes observed in MDD (Figure 4).”
10 of 10

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 227 references

Research works printed but not linked: 1

  1. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61 Suppl 6:7–11.

Cited by

Sorted by citations

See all 408

Metadata

Authors
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M.
Affiliations
  • Stanford Medicine (US)
  • Columbia University (US)
  • New York State Psychiatric Institute (US)
  • Columbia University Irving Medical Center (US)
Corresponding author
Boldrini, Maura
Venue
Molecular Psychiatry
Published
2022-03-30
Volume
27
Issue
6
Pages
2689-2699
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4221105875
Cited by
408
References
227
Citations by year
2026: 94 · 2025: 127 · 2024: 115 · 2023: 54 · 2022: 18
FWCI
11.28
Type
journal article
Language
en
Open access
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (R56AG063372, R01AG076949)
  • National Institute of Mental Health (R01MH083862, R21MH094888)
  • National Institute of Allergy and Infectious Diseases (R21AI164769)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, hippocampal plasticity, adult hippocampal neurogenesis, antidepressant mechanism, synaptic plasticity, depression pathogenesis, depression treatment
MeSH terms
Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Hippocampus, Humans, Neuronal Plasticity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review